Clinical Trials Sponsored by Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences

Total 815 results

Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Head and Neck Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer

Locally Recurrent Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Targeted Therapy | HR+/HER2- Advanced Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Advanced Lung Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

dMMR Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Rectal Cancer | MSS

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

Breast Cancer | Chemotherapy Effect

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Limited Stage Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

Patients With Advanced Solid Tumors

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma

Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications | Targetd Therapy

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma

Leiomyosarcoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Characteristics and Treatment Trends of Young Breast Cancer in China

Breast Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

Biosimilar

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC (CAPACITY)

Hormone Receptor Positive Advanced Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Refractory Lymphoma | DLBCL | MYD88 Gene Mutation | Relapse | CD79A Gene Mutation | CD79B Gene Mutation
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Hepatocellular Carcinoma Resectable
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Treatment Modalities in Esophageal Cancer

Esophageal Cancer | Chemoradiation | Surgery | Chemotherapy Effect | Immunotherapy | Targeted Therapy | Esophagogastric Juction Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Advanced Hepatocellular Carcinoma | Radiotherapy | Sorafenib | Toripalimab

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Untreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or Negative

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Triple Negative Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Triple Negative Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

HER2-positive Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy | Nasopharyngeal Squamous Cell Carcinoma | Stage II, III | Induction Chemotheray | Reduce Treatment Intensity

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer

Breast Neoplasms | Neoplasm Recurrence, Local

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

How do Super Lean Subjects Keep Resistant to Body Weight Gain?

Genetics | Health Behavior | Thinness

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Study of Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) for Rectosigmoid Cancer

Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Radiotherapy | Sintilimab | Concurrent Chemoradiotherapy | Immunonutrition | Locally Advanced Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer (MIS-MRC)

Locally Advanced Rectal Cancer | Distant Metastasis

China
Cancer Institute and Hospital, Chinese Academy...

Completed

HA-WBRT-SIB for Brain Metastasis of Lung Cancer

Cognitive Function | Brain Metastases | Lung Neoplasm | Simultaneous Integrated Boost | Hippocampal Avoidance

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer (MATCH)

Gastric Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic Resection

Esophageal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Sequence of Radiation and Targeted Therapy in Brain Metastases

The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer

Bladder Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer

Thoracic Neoplasms | Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Enrolling by invitation

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Diffuse Large B Cell Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

Colorectal Cancer | Metastatic Cancer | Colorectal Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Hemodynamic Changes During Dry Cupping Therapy on Low Back Pain

Muscle Spasticity | Oxygen Metabolism
Cancer Institute and Hospital, Chinese Academy...

Unknown

HFSRT With Concurrent TMZ for Large BMs

Chemotherapy | Brain Metastases | Radiotherapy

China

Clinical Trials Sponsored by Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations